Bruker Corporation stock hits 52-week low at 29.68 USD

Bruker Corporation stock recently reached a 52-week low, trading at $28.96, with the company maintaining a market capitalization of $5.05 billion. According to InvestingPro analysis, the company’s Fair Value suggests the stock may be undervalued at current levels. This milestone reflects a challenging period for the company, as it has experienced a substantial decline of 49.27% over the past year. Despite the stock’s performance, the company has maintained revenue growth of 10.36% and InvestingPro data shows net income is expected to grow this year. However, 11 analysts have recently revised their earnings expectations downward, suggesting continued near-term pressures. The decline in stock price over the past year indicates significant market pressures or company-specific challenges that have impacted investor confidence. As Bruker navigates these hurdles, stakeholders will be keenly observing any strategic adjustments or market developments that might influence future performance. For deeper insights into Bruker’s financial health and growth prospects, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.

In other recent news, Bruker Corporation announced a public offering of $600 million in Mandatory Convertible Preferred Stock, Series A, with an option for underwriters to purchase an additional $90 million. The proceeds are intended to repay several loans, including a term loan due December 2026 and outstanding borrowings under its 2024 amended revolving credit agreement. Additionally, Bruker declared a quarterly cash dividend of $0.05 per share, payable on October 3, 2025, to stockholders of record as of September 23, 2025. Analyst firms have made several adjustments to Bruker’s stock price targets. TD Cowen and Stifel both lowered their price targets to $40, citing weak demand and reduced academic spending, respectively, while maintaining a Hold rating. Meanwhile, JPMorgan reduced its target to $50 from $60 but kept an Overweight rating, highlighting Bruker’s strong 2024 guidance and 2027 targets despite challenging market conditions. These developments reflect recent shifts in Bruker’s financial strategy and market outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.